PK/PD Study Services for Obesity
Understanding the intricate relationship between drug exposure and therapeutic response is central to the development of effective obesity treatments. Our specialized pharmacokinetic/pharmacodynamic (PK/PD) research services are designed to elucidate these interactions, enabling the optimization of dosing regimens and the acceleration of obesity drug development. By integrating comprehensive PK/PD analyses, we help our partners translate preclinical findings into meaningful clinical outcomes, ensuring that new therapeutics are both safe and efficacious for obesity management.
We offer a broad spectrum of administration routes—including oral, intravenous, intraperitoneal, and intranasal—to support the investigation of diverse delivery strategies for anti-obesity agents. This flexibility allows for the assessment of absorption, distribution, and bioavailability across multiple modalities, ensuring that the most effective and patient-friendly delivery route is identified for each therapeutic candidate.
Our services encompass extensive compartment analysis across a wide range of biological matrices, including plasma, serum, blood, liver, adipose tissue, kidney, intestine, skeletal muscle, brain, and more. This capability enables precise quantification of drug concentrations and metabolites in key organs and tissues implicated in obesity pathophysiology, providing critical insights into tissue-specific distribution, target engagement, and pharmacological effects.
We employ advanced analytical platforms such as high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), mass spectrometry (including HPLC-MS, UPLC-MS, LC-MS), and enzyme-linked immunosorbent assay (ELISA). These methods facilitate highly sensitive and specific quantification of drug candidates and biomarkers, supporting robust PK/PD modeling, assay validation, and translational biomarker discovery.
Our preclinical studies utilize a diverse array of animal models, including mice, rats, minipigs, pigs, dogs, and non-human primates (monkeys). These models are selected for their physiological relevance to human obesity and metabolic disease, enabling rigorous evaluation of pharmacological effects, safety profiles, and translational potential across species.
Through integrated PK/PD studies, we deliver key insights into drug absorption, distribution, metabolism, and excretion (ADME) properties; concentration-effect relationships; dosing regimen optimization; and interspecies scaling to inform human dose projections. This comprehensive approach supports data-driven decision-making at every stage of obesity drug development.
With deep expertise in obesity research and a commitment to scientific excellence, we invite you to partner with us for your PK/PD study needs. Our end-to-end service capabilities ensure that your obesity therapeutic programs are supported by rigorous, actionable data—accelerating your path from discovery to clinical success.
Make Order
Experimental Scheme
Implementation
Conclusion
